A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent
(2016) In European Journal of Surgical Oncology 42(8). p.31-1123- Abstract
Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses... (More)
Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC.
(Less)
- author
- publishing date
- 2016-08
- type
- Contribution to journal
- publication status
- published
- keywords
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin/administration & dosage, Cytoreduction Surgical Procedures/methods, Docetaxel, Drug Combinations, Humans, Hyperthermia, Induced/methods, Infusions, Parenteral, Multivariate Analysis, Neoadjuvant Therapy, Oxonic Acid/administration & dosage, Peritoneal Neoplasms/secondary, Peritoneum/surgery, Stomach Neoplasms/pathology, Taxoids/administration & dosage, Tegafur/administration & dosage
- in
- European Journal of Surgical Oncology
- volume
- 42
- issue
- 8
- pages
- 31 - 1123
- publisher
- Elsevier
- external identifiers
-
- scopus:84965011465
- pmid:27160355
- ISSN
- 1532-2157
- DOI
- 10.1016/j.ejso.2016.03.016
- language
- English
- LU publication?
- no
- additional info
- Copyright © 2016 Elsevier Ltd. All rights reserved.
- id
- 750dca97-1d41-4720-83d4-d2c782c042d5
- date added to LUP
- 2022-04-05 09:37:01
- date last changed
- 2024-10-10 01:27:59
@article{750dca97-1d41-4720-83d4-d2c782c042d5, abstract = {{<p>Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication. In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed. Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC. </p>}}, author = {{Yonemura, Y and Canbay, E and Li, Y and Coccolini, F and Glehen, O and Sugarbaker, P H and Morris, D and Moran, B and Gonzaletz-Moreno, S and Deraco, M and Piso, P and Elias, D and Batlett, D and Ishibashi, H and Mizumoto, A and Verwaal, V and Mahtem, H}}, issn = {{1532-2157}}, keywords = {{Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cisplatin/administration & dosage; Cytoreduction Surgical Procedures/methods; Docetaxel; Drug Combinations; Humans; Hyperthermia, Induced/methods; Infusions, Parenteral; Multivariate Analysis; Neoadjuvant Therapy; Oxonic Acid/administration & dosage; Peritoneal Neoplasms/secondary; Peritoneum/surgery; Stomach Neoplasms/pathology; Taxoids/administration & dosage; Tegafur/administration & dosage}}, language = {{eng}}, number = {{8}}, pages = {{31--1123}}, publisher = {{Elsevier}}, series = {{European Journal of Surgical Oncology}}, title = {{A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent}}, url = {{http://dx.doi.org/10.1016/j.ejso.2016.03.016}}, doi = {{10.1016/j.ejso.2016.03.016}}, volume = {{42}}, year = {{2016}}, }